In-situ tumor vaccination: Bringing the fight to the tumor
Authors:
- Robert H PierceRPRobert H Pierce
- Jean S CampbellJCJean S Campbell
- Sara I PaiSPSara I Pai
- Joshua D BrodyJBJoshua D Brody
- Holbrook Ek KohrtHKHolbrook Ek Kohrt
- 29 May 2015
- journal article
- review article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 11 (8) , 1901-1909
Abstract
After decades of development in the shadow of traditional cancer treatment, immunotherapy has come into the spotlight. Treatment of metastatic tumors with monoclonal antibodies to T cell checkpoints like programed cell death 1 (PD-1) or its ligand, (PD-L1), have resulted in significant clinical responses across multiple tumor types. However, these therapies fail in the majority of patients with solid tumors, in particular those who lack PD1(+)CD8(+) tumor-infiltrating lymphocytes within their tumors. Intratumoral "in situ vaccination" approaches seek to enhance immunogenicity, generate tumor infiltrating lymophcytes (TIL) and drive a systemic anti-tumor immune response, directed against "unvaccinated," disseminated tumors. Given the emerging picture of intratumoral immunotherapy as safe and capable of delivering systemic efficacy, it is anticipated that these approaches will become integrated into future multi-modality therapy.Keywords
This publication has 86 references indexed in Scilit:
- Depleting tumor-specific Tregs at a single site eradicates disseminated tumorsJournal of Clinical Investigation, 2013
- An obligate cell-intrinsic function for CD28 in TregsJournal of Clinical Investigation, 2013
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 AntibodyClinical Cancer Research, 2009
- Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenaseProceedings of the National Academy of Sciences, 2008
- Molecular characteristics of immunogenic cancer cell deathCell Death & Differentiation, 2007
- Tumor stress, cell death and the ensuing immune responseCell Death & Differentiation, 2007
- The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapyImmunological Reviews, 2007
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapyJournal of Experimental Medicine, 2006